The FDA Said No. Then It Said Yes. Now This Gene Therapy Could Change Everything.
The FDA told uniQure its Huntington's disease gene therapy data weren't good enough to file for approval. Then the agency reversed course. Now AMT-130 could become the first treatment that actually slows a disease with zero disease-modifying options.
A Disease With No Real Treatment Just Got a Lifeline
Huntington's disease is about as cruel as neurology gets. It's genetic, progressive, and fatal. Patients slowly lose the ability to move, think, and swallow. Most survive about 15 to 20 years after symptoms appear. And for all of modern medicine's progress, there is still no approved therapy that actually slows the disease down.
Every drug on the market for Huntington's is a Band-Aid. Medications can reduce involuntary movements (chorea) or manage depression and anxiety. Physical therapy helps. But nothing touches the underlying neurodegeneration. The disease keeps marching forward no matter what you throw at it.
That's what makes this week's news so significant. uniQure just filed for U.S. approval of AMT-130, a one-time gene therapy delivered directly into the brain. If approved, it would be the first disease-modifying treatment for Huntington's disease, ever.
But the story of how this filing happened is almost as dramatic as what the drug does.
The Regulatory Roller Coaster Nobody Saw Coming
Rewind to late 2025. uniQure had promising data from its Phase I/II trial and was gearing up to file a Biologics License Application (a BLA, essentially the formal ask for FDA approval). The company planned to use its clinical trial results alongside an external control group, comparing treated patients to a matched set of untreated patients from historical data rather than running a traditional head-to-head trial.
Then the FDA threw cold water on the whole plan.
The agency told uniQure that the external-control approach wasn't good enough. The FDA pushed hard for a new, prospective trial: randomized, double-blind, and sham-surgery-controlled. That's the gold standard, sure. But for a fatal neurodegenerative disease with zero disease-modifying options, it would have meant years of additional delay. Patients who might benefit would have to wait. uniQure's stock took a hit, and the path forward looked bleak.
Then something unusual happened. The FDA changed its mind.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
By mid-2026, after what the company described as further discussions with the agency, the FDA reversed course. It agreed that uniQure's three-year Phase I/II data could support a filing for accelerated approval. Even better, the agency dropped its insistence on a sham-surgery confirmatory trial, opening the door to a study using standard-of-care controls instead.
On September 2, 2026, uniQure submitted the BLA. The company also requested priority review, which would shorten the FDA's decision timeline.
What the Data Actually Show
Let's talk about results, because the numbers matter here.
The headline finding: patients who received the high dose of AMT-130 showed a 75% slowing of disease progression at 36 months compared to the external control group. That was measured using the cUHDRS, a composite score that captures motor function, cognitive ability, and overall independence. Treated patients declined by an average of 0.38 points from baseline, while the control group dropped 1.52 points. The difference was statistically significant (p=0.003).
There's a useful analogy here. Imagine two cars rolling downhill toward a cliff. The untreated car is barreling ahead at full speed. The treated car is still moving, but someone hit the brakes hard enough to cut the speed by three-quarters. It's not a cure; the car is still rolling. But the extra time matters enormously.
On a secondary measure called Total Functional Capacity (which tracks a patient's ability to handle daily life), the high-dose group showed a 60% slowing of decline versus controls. That result was also statistically significant.
Safety looked reasonable too. The company reported a manageable safety profile with no new serious adverse effects since late 2022.
Now, the caveats. This was a small study: the primary analysis included 10 patients in the low-dose cohort and 16 in the high-dose cohort. And the comparison was against an external control, not a randomized group within the same trial. Critics will rightfully point out that external controls can introduce bias. That's exactly why the FDA initially balked.
But for a uniformly fatal disease with no alternatives, the bar for "good enough" looks different.
One Shot to the Brain
AMT-130 (nonproprietary name: ifezuntirgene inilparvovec, because of course) isn't your typical pill or infusion. It's a single neurosurgical procedure. Doctors use MRI-guided, convection-enhanced stereotactic delivery to inject the therapy directly into the striatum, the brain region most affected by Huntington's.
One treatment. One time. That's the promise of gene therapy: fix the problem at its source rather than managing symptoms for the rest of a patient's shortened life.
The therapy has already racked up an impressive collection of FDA designations. It holds Regenerative Medicine Advanced Therapy (RMAT), Breakthrough Therapy, and Fast Track status. Each of those signals that the agency considers this a potentially important drug for a serious condition.
Wall Street Is Paying Attention
uniQure's stock jumped in premarket trading on the filing news, though it gave back some gains as investors weighed the remaining regulatory uncertainty. The consensus among analysts is cautiously optimistic: 17 analysts carry a Moderate Buy rating with an average price target of $65, implying roughly 36% upside from recent levels. William Blair reinstated coverage with an Outperform rating the same day the BLA was submitted.
The bigger question for investors isn't just whether the FDA accepts the filing. It's what approval would look like commercially. Recent gene therapy approvals have come with eye-popping price tags; one therapy approved in 2026 for glycogen storage disease launched at $2.7 million per patient. A one-time brain surgery for a rare, fatal disease could command a similar premium.
But pricing is only half the equation. Manufacturing complexity, surgical logistics, and payer pushback remain real obstacles. Several genetic therapies failed to secure FDA approval in the past year, a reminder that nothing is guaranteed in this space.
Why This Matters Beyond the Stock Ticker
Step back from the business side for a moment. Roughly 41,000 people in the U.S. have symptomatic Huntington's disease, and many more carry the gene that will eventually trigger it. Every single one of them knows what's coming. There's a genetic test that can tell you decades in advance whether you'll develop the disease, but until now, knowing your fate came with no way to change it.
AMT-130 isn't a cure. The data show slowing, not stopping. And accelerated approval (if granted) would come with the requirement for a confirmatory study to prove the benefit holds up over time.
But for a community that has watched every promising therapy fail, from Roche's tominersen to Wave Life Sciences' early setbacks, a filed BLA with solid three-year data and the FDA's blessing to proceed feels like something genuinely new.
The FDA now has the ball. If priority review is granted, a decision could come within months rather than the standard year-long timeline. For thousands of families watching the clock tick on a disease that steals everything, that timeline matters more than any stock price.
Clinical & Regulatory4 min read
Zero Relapses in Three Years: The Cancer Vaccine That Won't Blink
A personalized cancer vaccine just posted 100% disease-free survival at three years in one of oncology's toughest cancers. Sixteen patients, zero relapses, and a field watching very closely.
